[Use Case] Reformulation prospects to reduce mild but unpleasant AEs

[kristinlindquist]

"The pharma giant designed danuglipron as a twice-daily drug, but that approach ended in December with poor tolerability in a Phase IIb trial in adults with obesity. The pill had discontinuation rates of more than 50% across all doses compared to 40% discontinuation for placebo. The asset was also linked with high levels of nausea (73%), vomiting (47%) and diarrhea (25%)."